Clinical trial
A Study to Assess Antibody Persistence, Boostability & Safety in Previously…
NCT00317174 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00317174 |
|---|---|
| Title | A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. |
| Official title | Assess Immune Persistence & Memory by Giving Plain PRP,PSA & PSC (10 Mths Age), & Immunogenicity & Safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b, Tetanus, Whole Cell Pertussis, Hepatitis B, Diphtheria |
| Intervention type | Biological |
| Interventions | DTPw-HBV/Hib-MenAC conjugate vaccine |
| Enrollment | 450 |
| Start date | Jul 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | Apr 24, 2006 |
| Last update posted | Sep 9, 2016 |
| Countries | Philippines |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: